LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

Search

Xenon Pharmaceuticals Inc

Abierto

SectorSalud

29.46 -1.01

Resumen

Variación precio

24h

Actual

Mínimo

29

Máximo

30.01

Métricas clave

By Trading Economics

Ingresos

-2.9M

-66M

BPA

-0.84

Empleados

316

EBITDA

-3.8M

-77M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+82.7% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-179M

2.7B

Apertura anterior

30.47

Cierre anterior

29.46

Noticias sobre sentimiento de mercado

By Acuity

22%

78%

49 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

14 may 2025, 23:40 UTC

Acciones populares

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 may 2025, 23:33 UTC

Principales Movimientos del Mercado

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 may 2025, 23:25 UTC

Principales Movimientos del Mercado

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 may 2025, 23:25 UTC

Ganancias

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 may 2025, 22:58 UTC

Ganancias

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 may 2025, 21:35 UTC

Ganancias

Cisco Systems Names Patterson as CFO, Patel as President

14 may 2025, 23:59 UTC

Charlas de Mercado

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 may 2025, 23:49 UTC

Charlas de Mercado

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 may 2025, 23:48 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2025, 23:48 UTC

Charlas de Mercado

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 may 2025, 23:47 UTC

Charlas de Mercado

Gold Gains on Possible Technical Recovery -- Market Talk

14 may 2025, 23:34 UTC

Adquisiciones, fusiones, absorciones

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 may 2025, 23:10 UTC

Ganancias

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 may 2025, 23:07 UTC

Ganancias

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 may 2025, 23:00 UTC

Principales Noticias

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 may 2025, 22:43 UTC

Ganancias

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 may 2025, 22:34 UTC

Ganancias

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 may 2025, 22:33 UTC

Ganancias

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero Did Not Declare a Dividend>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 may 2025, 22:28 UTC

Ganancias

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 may 2025, 22:28 UTC

Ganancias

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 may 2025, 22:27 UTC

Ganancias

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 may 2025, 22:27 UTC

Ganancias

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 may 2025, 22:23 UTC

Principales Noticias

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 may 2025, 22:15 UTC

Ganancias

Correction to Cisco Earnings Article -- WSJ

14 may 2025, 21:48 UTC

Ganancias

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 may 2025, 21:37 UTC

Ganancias

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Comparación entre iguales

Cambio de precio

Xenon Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

82.7% repunte

Estimación a 12 meses

Media 54.08 USD  82.7%

Máximo 65 USD

Mínimo 42 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

15

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

34.81 / 38.24Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

49 / 382 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.